- Clinical Associate Professor, Global Health
Select from the following:
Andreas Jahn is a clinical epidemiologist with 20 years of working experience in Africa, primarily in HIV. He has worked the in the academic and program sector. Dr Jahn has published over 100 papers in peer-reviewed journals, including the first evidence globally for a population-level impact of ART roll-out on adult mortality (The Lancet, 2008). As of January 2020, his publications have received 2,417 citations and his h-index stands at 27 (Scopus). He has profoundly contributed to the National ART/PMTCT Program in Malawi which is widely recognized for the best M&E system and service data in resource-limited settings. He continues to shape national and international HIV programs and policy with innovative monitoring systems and initiatives such as Option B+ for PMTCT, which has been adopted as a global recommendation by WHO in 2013. He has contributed as an external expert on the WHO clinical HIV guideline development committee since 2012.
- PhD (London School of Hygiene & Tropical Medicine (UK))
- MSc (London School of Hygiene & Tropical Medicine (UK))
- MBBS (Freie University of Berlin (Germany))
- Disease Surveillance
- Education and Training
- Health Information Systems
- Health Policy
- HIV Transmission
- Implementation Science
- Infectious Diseases
- Metrics and Evaluation
- Operations Research
HIV/AIDS, operations research, task shifting
- Development of a new streamlined monitoring and reporting system for the national HIV testing program in Malawi
- Development of routine monitoring and surveillance methods for progress towards elimination of mother to child transmission of HIV
- I-TECH Malawi
- Low-level viremia and patient outcomes in the Malawi HIV program after transition to dolutegravir-based first and second-line ART
- National and sub-national estimation of HIV prevalence incidence and coverage of antiretroviral therapy
1. Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, et al. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. Lancet HIV 2020;7:e193–200. https://doi.org/10.1016/S2352-3018(19)30400-X.
2. Eaton JW, Terris-Prestholt F, Cambiano V, Sands A, Baggaley RC, Hatzold K, Corbett EL, Kalua T, Jahn A, Johnson CC. Optimizing HIV testing services in sub-Saharan Africa: cost and performance of verification testing with HIV self-tests and tests for triage. J Int AIDS Soc 2019;22. https://doi.org/10.1002/jia2.25237.
3. Landes M, van Lettow M, Nkhoma E, Tippett Barr B, Truwah Z, Schouten E, Jahn A, Auld A, Kalua T, van Oosterhout JJ. Low detectable postpartum viral load is associated with HIV transmission in Malawi’s prevention of mother-to-child transmission programme. J Int AIDS Soc 2019;22. https://doi.org/10.1002/jia2.25290.
4. Maheu-Giroux M, Jahn A, Kalua T, Mganga A, Eaton JW. HIV
surveillance based on routine testing data from antenatal clinics in Malawi (2011-2018): measuring and adjusting for bias from imperfect testing coverage. AIDS 2019;33 Suppl 3:S295–302. https://doi.org/10.1097/QAD.0000000000002356.
5. Maheu-Giroux M, Marsh K, Doyle CM, Godin A, Lanièce Delaunay C, Johnson LF, Jahn A, Abo K, Mbofana F, Boily M-C, Buckeridge DL, Hankins CA, Eaton JW. National HIV testing and diagnosis coverage in sub-Saharan Africa: a new modeling tool for estimating the “first 90” from program and survey data. AIDS 2019;33 Suppl 3:S255–69. https://doi.org/10.1097/QAD.0000000000002386.